Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Ursodeoxycholic Acid (UDCA) Promotes Lactate Metabolism in Mouse Hepatocytes through Cholic Acid (CA) - Farnesoid X Receptor (FXR) Pathway

Author(s): Lu Wang, Huai-Wu He, Xiang Zhou* and Yun Long*

Volume 20, Issue 8, 2020

Page: [661 - 666] Pages: 6

DOI: 10.2174/1566524020666200123161340

Price: $65

Abstract

Background: Persistent hyperlactatemia is associated with greater mortality in shock. Liver is the main site of lactate metabolism.

Method: In the first part, freshly isolated hepatocytes were incubated in 10% fetal bovine serum William's E medium supplemented with 10 mM lactate. Cells were then exposed to 100 μM ursodeoxycholic acid (UDCA), with no addition (control) for 2, 4, 6, 8 h. In the second part, hepatocytes were treated with Silencer select siRNA targeting FXR or scramble siRNA. The siRNA treatment was repeated twenty four hours later, and the cells were used in the experiments twenty-four hours after the second treatment. Then hepatocytes were incubated in 10% fetal bovine serum William's E medium supplemented with 10 mM lactate. Cells were then exposed to 100 μM UDCA for 2, 4, 6, 8 h. Lactate concentration was determined by ABL80 automatic blood gas analyzer.

Results: UDCA increased ability of hepatocytes to remove lactate. After the knockdown of FXR, effects caused by UDCA were weakened.

Conclusion: These results demonstrate that UDCA promotes lactate metabolism in mouse hepatocytes through CA-FXR pathway.

Keywords: Lactate, ursodeoxycholic acid, cholic acid, farnesoid X receptor, hepatocytes, hyperlactatemia.

« Previous
[1]
Rosenstein PG, Tennent-Brown BS, Hughes D. Clinical use of plasma lactate concentration. Part 2: Prognostic and diagnostic utility and the clinical management of hyperlactatemia. J Vet Emerg Crit Care (San Antonio) 2018; 28(2): 106-21.
[http://dx.doi.org/10.1111/vec.12706] [PMID: 29533517]
[2]
Bolvardi E, Malmir J, Reihani H, et al. The Role of Lactate Clearance as a Predictor of Organ Dysfunction and Mortality in Patients with Severe Sepsis. Mater Sociomed 2016; 28(1): 57-60.
[http://dx.doi.org/10.5455/msm.2016.28.57-60] [PMID: 27047270]
[3]
Haas SA, Lange T, Saugel B, et al. Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients. Intensive Care Med 2016; 42(2): 202-10.
[http://dx.doi.org/10.1007/s00134-015-4127-0] [PMID: 26556617]
[4]
Zhou X, Liu D, Su L. Lactate and stepwise lactate kinetics can be used to guide resuscitation. Crit Care 2017; 21(1): 267.
[http://dx.doi.org/10.1186/s13054-017-1859-y] [PMID: 29078796]
[5]
Zhou X, Liu D, Su L. Response to: Understanding the null hypothesis (H0) in non-inferiority trials. Crit Care 2017; 21(1): 201.
[http://dx.doi.org/10.1186/s13054-017-1790-2] [PMID: 28774313]
[6]
Zhou X, Liu D, Su L, et al. Use of stepwise lactate kinetics-oriented hemodynamic therapy could improve the clinical outcomes of patients with sepsis-associated hyperlactatemia. Crit Care 2017; 21(1): 33.
[http://dx.doi.org/10.1186/s13054-017-1617-1] [PMID: 28202033]
[7]
Arnold RC, Shapiro NI, Jones AE, et al. Emergency Medicine Shock Research Network (EMShockNet) Investigators. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Shock 2009; 32(1): 35-9.
[http://dx.doi.org/10.1097/SHK.0b013e3181971d47] [PMID: 19533847]
[8]
Odom SR, Howell MD, Silva GS, et al. Lactate clearance as a predictor of mortality in trauma patients. J Trauma Acute Care Surg 2013; 74(4): 999-1004.
[http://dx.doi.org/10.1097/TA.0b013e3182858a3e] [PMID: 23511137]
[9]
Zhang Z, Xu X. Lactate clearance is a useful biomarker for the prediction of all-cause mortality in critically ill patients: a systematic review and meta-analysis*. Crit Care Med 2014; 42(9): 2118-25.
[http://dx.doi.org/10.1097/CCM.0000000000000405] [PMID: 24797375]
[10]
Gao F, Huang XL, Cai MX, et al. Prognostic value of serum lactate kinetics in critically ill patients with cirrhosis and acute-on-chronic liver failure: a multicenter study. Aging (Albany NY) 2019; 11(13): 4446-62.
[http://dx.doi.org/10.18632/aging.102062] [PMID: 31259742]
[11]
Takahashi K, Jafri SR, Safwan M, Abouljoud MS, Nagai S. Peri-transplant lactate levels and delayed lactate clearance as predictive factors for poor outcomes after liver transplantation: A propensity score-matched study. Clin Transplant 2019; 33(7)e13613
[http://dx.doi.org/10.1111/ctr.13613] [PMID: 31119814]
[12]
Li G. L Guo G. Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration. Acta Pharm Sin B 2015; 5(2): 93-8.
[http://dx.doi.org/10.1016/j.apsb.2015.01.005] [PMID: 26579433]
[13]
Huang W, Ma K, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006; 312(5771): 233-6.
[http://dx.doi.org/10.1126/science.1121435] [PMID: 16614213]
[14]
Miura T, Tachikawa M, Ohtsuka H, et al. Application of Quantitative Targeted Absolute Proteomics to Profile Protein Expression Changes of Hepatic Transporters and Metabolizing Enzymes During Cholic Acid-Promoted Liver Regeneration. J Pharm Sci 2017; 106(9): 2499-508.
[http://dx.doi.org/10.1016/j.xphs.2017.02.018] [PMID: 28249806]
[15]
Bodewes FA, Bijvelds MJ, de Vries W, et al. Cholic acid induces a Cftr dependent biliary secretion and liver growth response in mice. PLoS One 2015; 10(2)e0117599
[http://dx.doi.org/10.1371/journal.pone.0117599] [PMID: 25680200]
[16]
Hongguang J, Xingjie H, Mingliang J, et al. Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease. Pak J Pharm Sci 2019; 32(1(Special)): 433-7.
[17]
Leoni MC, Amelung L, Lieveld FI, et al. Adherence to ursodeoxycholic acid therapy in patients with cholestatic and autoimmune liver disease. Clin Res Hepatol Gastroenterol 2019; 43(1): 37-44.
[http://dx.doi.org/10.1016/j.clinre.2018.08.006] [PMID: 30219692]
[18]
Kim DJ, Yoon S, Ji SC, et al. Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. Sci Rep 2018; 8(1): 11874.
[http://dx.doi.org/10.1038/s41598-018-30349-1] [PMID: 30089798]
[19]
Lu Y, Zheng W, Lin S, et al. Identification of an Oleanane-Type Triterpene Hedragonic Acid as a Novel Farnesoid X Receptor Ligand with Liver Protective Effects and Anti-inflammatory Activity. Mol Pharmacol 2018; 93(2): 63-72.
[http://dx.doi.org/10.1124/mol.117.109900] [PMID: 29162643]
[20]
Halilbasic E, Fuchs C, Traussnigg S, Trauner M, Farnesoid X, Farnesoid X. Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. Dig Dis 2016; 34(5): 580-8.
[http://dx.doi.org/10.1159/000445268] [PMID: 27332721]
[21]
Mroz MS, Lajczak NK, Goggins BJ, Keely S, Keely SJ. The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing. Am J Physiol Gastrointest Liver Physiol 2018; 314(3): G378-87.
[http://dx.doi.org/10.1152/ajpgi.00435.2016] [PMID: 29351391]
[22]
Chung J, An SH, Kang SW, Kwon K. Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis. PLoS One 2016; 11(1)e0147839
[http://dx.doi.org/10.1371/journal.pone.0147839] [PMID: 26807573]
[23]
Sun J, Li M, Fan S, et al. A novel liver-targeted nitric oxide donor UDCA-Thr-NO protects against cirrhosis and portal hypertension. Am J Transl Res 2018; 10(2): 392-401.
[PMID: 29511433]
[24]
Zhu GQ, Shi KQ, Huang S, et al. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. Medicine (Baltimore) 2015; 94(11)e609
[http://dx.doi.org/10.1097/MD.0000000000000609] [PMID: 25789951]
[25]
Mueller M, Castro RE, Thorell A, Marschall HU, Auer N, Herac M, et al. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients Liver international : official journal of the International Association for the Study of the Liver 2018; 38(3): 523-31.
[http://dx.doi.org/10.1111/liv.13562] [PMID: 5836915]
[26]
Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284(5418): 1365-8.
[http://dx.doi.org/10.1126/science.284.5418.1365] [PMID: 10334993]
[27]
Xiang D, Yang J, Liu Y, et al. Calculus Bovis Sativus Improves Bile Acid Homeostasis via Farnesoid X Receptor-Mediated Signaling in Rats With Estrogen-Induced Cholestasis. Front Pharmacol 2019; 10: 48.
[http://dx.doi.org/10.3389/fphar.2019.00048] [PMID: 30774596]
[28]
Zhang Y, Jackson JP, St Claire RL III, Freeman K, Brouwer KR, Edwards JE. Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. Pharmacol Res Perspect 2017; 5(4)
[http://dx.doi.org/10.1002/prp2.329] [PMID: 28805978]
[29]
Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294(5548): 1866-70.
[http://dx.doi.org/10.1126/science.294.5548.1866] [PMID: 11729302]
[30]
Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89(1): 147-91.
[http://dx.doi.org/10.1152/physrev.00010.2008] [PMID: 19126757]
[31]
Wang N, Zou Q, Xu J, Zhang J, Liu J. Ligand binding and heterodimerization with retinoid X receptor α (RXRα) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding. J Biol Chem 2018; 293(47): 18180-91.
[http://dx.doi.org/10.1074/jbc.RA118.004652] [PMID: 30275017]
[32]
Giaginis C, Koutsounas I, Alexandrou P, et al. Elevated Farnesoid X Receptor (FXR) and Retinoid X Receptors (RXRs) expression is associated with less tumor aggressiveness and favourable prognosis in patients with pancreatic adenocarcinoma. Neoplasma 2015; 62(2): 332-41.
[http://dx.doi.org/10.4149/neo_2015_040] [PMID: 25591600]
[33]
Maloney PR, Parks DJ, Haffner CD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000; 43(16): 2971-4.
[http://dx.doi.org/10.1021/jm0002127] [PMID: 10956205]
[34]
Flatt B, Martin R, Wang TL, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem 2009; 52(4): 904-7.
[http://dx.doi.org/10.1021/jm8014124] [PMID: 19159286]
[35]
Cao Y, Xiao Y, Zhou K, et al. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection. Am J Physiol Gastrointest Liver Physiol 2019; 317(2): G108-15.
[http://dx.doi.org/10.1152/ajpgi.00356.2017] [PMID: 30920307]
[36]
Kim I, Ahn SH, Inagaki T, et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 2007; 48(12): 2664-72.
[http://dx.doi.org/10.1194/jlr.M700330-JLR200] [PMID: 17720959]
[37]
Borude P, Edwards G, Walesky C, et al. Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice. Hepatology 2012; 56(6): 2344-52.
[http://dx.doi.org/10.1002/hep.25918] [PMID: 22730081]
[38]
Manley S, Ding W. Role of farnesoid X receptor and bile acids in alcoholic liver disease. Acta Pharm Sin B 2015; 5(2): 158-67.
[http://dx.doi.org/10.1016/j.apsb.2014.12.011] [PMID: 26579442]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy